FAQ: What retina specialists need to know about the MOGENRY (MCO-010) BLA acceptance

The US Food and Drug Administration has accepted and filed Nanoscope Therapeutics' Biologics License Application for sonpiretigene isteparvovec (MOGENRY; Nanoscope Therapeutics), an intravitreal optogenetic gene therapy for adults with retinitis pigmentosa (RP) and severe vision loss. If approved, the agent would become the first gene-agnostic therapy for this population.¹